Adding the monoclonal anti-HER2 antibody trastuzumab to standard chemotherapy resulted in a significant improvement in the progression-free survival (PFS) and overall survival (OS) in patients with metastatic HER2-positive BC [7]. This evidence concerns the gene ERBB2 and breast cancer.